A clinical study on anti-HBV-DC-MTL in the HBeAg negative chronic hepatitis B virus infection

Abstract

Event Abstract Back to Event A clinical study on anti-HBV-DC-MTL in the HBeAg negative chronic hepatitis B virus infection Bang-FU Wu1, 2* and Jiang-Ying Yang2 1 Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, China 2 Guangzhou Pubang Bio-Immunological Tech Research Institute, China Aims: To observe the clinical efficacy of anti-HBV-DC-MTL, the dendritic cells(DC) and mixed T lymphocyte(MTL) originating from PBMC sensitized by HBsAg, in HBeAg negative chronic hepatitis B virus(HBV) infection. Methods: 19 inactive HBsAg carriers and 19 chronic hepatitis B(CHB) patients were recruited in the study.PBMCs were obtained from 50ml peripheral blood. Anti-HBV-DC was proliferated from adherence PBMCs under the induction by GM-CSF and IL-4, and sensitized with 50µg HBsAg. Anti-HBV-MTL was proliferated from no-adherence PBMCs under the induction by IL-2, IL-12 and anti-HBV-DC. Anti-HBV-DC was harvested on day 7 and injected, half hypodermically and half intravenously, to patient once every two weeks for 12 times totally. Anti-HBV-MTL was harvested on day 14 and injected intravenously to patient once every two weeks for 12 times totally. Telbivudine was taken 600mg daily for 10 CHB patients those HBVDNA>10000 copy/ml. Quantitative HBVM(TRFIA) and HBVDNA were evaluated at week 0, 4, 12, and 24. Results: Mean of HBsAg and HBVDNA decreased significantly at week 4, 12 and 24, HBsAg negative conversion rate were 10.53%(2/19), 15.79(3/19) and 21.05%(4/19) respectively, HBVDNA negative conversion rate were 69.23%(9/13), 76.92%(10/13) and 92.31%(12/13) in HBeAg negative CHB patients. Mean of HBsAg decreased gradually along the time from week 4, 12 to 24,in inactive HBsAg carriers. At week 4, 12 and 24, HBsAg negative conversion rate were 15.79%(3/19), 26.32%(5/19) and 36.84%(7/19) respectively. Conclusions: Anti-HBV-DC-MTL can effectively inhibit the viral replication, decrease rapidly and eliminate the HBsAg, and may eliminate the HBsAg for partial patients. Keywords: Dendritic Cells (DC), Mixed T lymphocyte (MTL), Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Inactive HBsAg carriers Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Translational immunology and immune intervention Citation: Wu B and Yang J (2013). A clinical study on anti-HBV-DC-MTL in the HBeAg negative chronic hepatitis B virus infection. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00894 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 20 Jun 2013; Published Online: 22 Aug 2013. * Correspondence: Prof. Bang-FU Wu, Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, Dongguan, Guangdong, 523952, China, bangfu.wu@163.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Bang-FU Wu Jiang-Ying Yang Google Bang-FU Wu Jiang-Ying Yang Google Scholar Bang-FU Wu Jiang-Ying Yang PubMed Bang-FU Wu Jiang-Ying Yang Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.